experspadmin

Gene Signature Predicts Survival Benefits With Immunotherapy for mCRPC
Oncology

Gene Signature Predicts Survival Benefits With Immunotherapy for mCRPC

clinical study insights
By William K. Oh, MD
Gallium PSMA PET/CT May Influence Management Plan in High Proportion of Patients
Oncology

Gallium PSMA PET/CT May Influence Management Plan in High Proportion of Patients

patient care perspectives
By William K. Oh, MD
Metastatic Consequences of Advanced Prostate Cancer
Oncology

Metastatic Consequences of Advanced Prostate Cancer

expert roundtables
By E. David Crawford, MD; Leonard Gomella, MD; Neal D. Shore, MD, FACS; Peter R. Carroll, MD, MPH
Defining Oligometastatic Disease and Treatment Implications
Oncology

Defining Oligometastatic Disease and Treatment Implications

expert roundtables
By E. David Crawford, MD; Leonard Gomella, MD; Neal D. Shore, MD, FACS; Peter R. Carroll, MD, MPH
Survival Benefit and Quality of Life Outcomes in Prostate Cancer
Oncology

Survival Benefit and Quality of Life Outcomes in Prostate Cancer

expert roundtables
By Daniel J. George, MD; Glen Gejerman, MD; Oliver Sartor, MD; William K. Oh, MD
Load More